BYSI - BeyondSpring Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 17.57 |
| Open | 17.51 |
| Bid | 16.80 x 900 |
| Ask | 17.21 x 1000 |
| Day's Range | 17.02 - 17.60 |
| 52 Week Range | 9.38 - 24.80 |
| Volume | 30,923 |
| Avg. Volume | 43,518 |
| Market Cap | 479.689M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings Date | Apr 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.80 |
Fair Value
Related Research
- GlobeNewswire
BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients
BeyondSpring (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent, U.S. 10,596,169, for methods of treating severe chemotherapy-induced neutropenia (CIN) from Taxane in cancer patients by administering its lead asset Plinabulin, with protection through 2033. “This is the first U.S. patent establishing Plinabulin’s beneficial effects in reducing CIN associated with taxane, one of the most commonly used chemotherapies,” said Dr. Lan Huang, BeyondSpring’s Co-founder, Chairman and CEO, and the inventor of this patent.
- Motley Fool
BeyondSpring Inc. (BYSI) Q4 2019 Earnings Call Transcript
Image source: The Motley Fool. BeyondSpring Inc. (NASDAQ: BYSI)Q4 2019 Earnings CallApr 30, 2020, 9:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to BeyondSpring's Fourth Quarter and Full Year 2019 Financial Results Conference Call.
- GlobeNewswire
BeyondSpring Files 2019 Annual Report on Form 20-F
NEW YORK, April 30, 2020 -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative.
- GlobeNewswire
BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update
- FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - -.
- GlobeNewswire
FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that, following discussions with the U.S. Food and Drug Administration (FDA), the Company has formally changed the primary endpoint for its Study 106 Phase 3 superiority clinical trial with first-in-class lead asset, Plinabulin, for chemotherapy-induced neutropenia (CIN) prevention. For more than 20 years, the standard primary endpoint for CIN trials has been the duration of severe (Grade 4) neutropenia (DSN).
- GlobeNewswire
BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its fourth-quarter and full-year 2019 financial results and host an operational update conference call on Thursday, April 30, 2020, at 8 a.m. Eastern Time. BeyondSpring is a global clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway.
- GlobeNewswire
BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company headquartered in New York focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated the rolling submission of its New Drug Application (NDA) with the Company’s lead asset, Plinabulin, for the chemotherapy-induced neutropenia indication to China’s National Medical Products Administration (NMPA). “Commencing the NDA rolling submission in China marks a significant milestone for BeyondSpring, bringing Plinabulin one step closer to commercialization to enhance the lives of cancer patients,” said Dr. Lan Huang, BeyondSpring’s co-founder and CEO.
- Simply Wall St.
One Thing To Remember About The BeyondSpring Inc. (NASDAQ:BYSI) Share Price
If you own shares in BeyondSpring Inc. (NASDAQ:BYSI) then it's worth thinking about how it contributes to the...
- GlobeNewswire
BeyondSpring’s Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company will present new clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing its potential ability to prevent tissue iron overload, a common cause of vital organ damages, in cancer patients who are receiving chronic blood transfusions as a result of their chemotherapy. Dr. Ramon Mohanlal, BeyondSpring’s Chief Medical Officer and Executive Vice President, Research and Development, will present the data as a poster at this year’s National Comprehensive Cancer Network (NCCN) Annual Conference.
- GlobeNewswire
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the submission of a provisional U.S. patent application for its pipeline asset BPI-002, for methods of treating viral infections, including COVID-19, when administered alone or in combination with a vaccine. BPI-002 can potentially activate the adaptive immune system (including CD4+ helper T cells and CD8+ cytotoxic T cells), the body’s strongest line of defense, to directly attack and kill virally infected cells, including RNA virus, such as those causing COVID-19.
- GlobeNewswire
BeyondSpring’s Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that new clinical data on the Company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system. Previously, the Company reported that Plinabulin stimulates the adaptive immune system, through enhancing Dendritic Cell-dependent T-Cell proliferation (Mita, ASCO-SITC 2017).
- GlobeNewswire
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointments of Drs. Daniel Zabrowski and Ramon Mohanlal to the Company’s Board of Directors. Dr. Zabrowski previously worked for more than 20 years at Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations and Global Head of Pharma Partnering.
- GlobeNewswire
BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced today the appointment of Dr. James Tonra, Ph.D. as Chief Science Officer, effective immediately. Dr. Tonra had previously served as Senior Vice President, Preclinical Development at BeyondSpring since April 2018.
- GlobeNewswire
BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer reviewed journal Cancer Chemotherapy and Pharmacology published a report on the unique mechanism of action (MoA) of the Company’s lead asset, Plinabulin. The report demonstrates that Plinabulin can successfully treat chemotherapy-induced neutropenia (CIN) caused by multiple chemotherapies.
- GlobeNewswire
BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update
Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 Plinabulin’s Anti-Cancer and CIN Prevention Mechanism Published in Peer.
- GlobeNewswire
BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will host its third-quarter 2019 financial results and operational update conference call on Wednesday, December 18, 2019, at 8 a.m. Eastern Time. BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.
- GlobeNewswire
BeyondSpring’s Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s abstract for its Phase 3 Study 106 clinical trial design with lead asset, Plinabulin, for chemotherapy-induced neutropenia (CIN) prevention was accepted for poster presentation at this year’s American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The abstract titled, “A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (Plin) + Pegfilgrastim (Peg) versus (vs) Peg Alone for TAC (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (CIN),” provides rationale for combining Plinabulin with Pegfilgrastim (Neulasta) due to their differing mechanisms of action for preventing CIN.
- GlobeNewswire
BeyondSpring’s Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin’s Mechanism of Action for CIN Accepted at American Society of Hematology’s 2019 Annual Meeting
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two Company abstracts on the unique mechanism of action for its lead asset, Plinabulin, have been accepted as e-publications at this year’s American Society of Hematology’s (ASH) Annual Meeting, taking place on December 7 through 10 in Orlando, Fla.
- GlobeNewswire
BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company’s novel trial design for Study 103 with lead asset, Plinabulin, was selected for poster presentation at this year’s Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD. The poster, titled, “Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3,” was presented on November 9. As cancer patients generally prefer immunotherapy over chemotherapy, they may prematurely withdraw their consent to participate in a clinical trial if they are allocated to the chemotherapy comparator arm, which may negatively impact the study’s outcome.
- GlobeNewswire
BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has appointed Gregg Russo as Senior Vice President, Human Resources, effectively immediately. “We are excited to Bring Mr. Russo on board as we move closer toward regulatory approval and potential commercialization of our lead compound, Plinabulin, for the treatment of non-small cell lung cancer and chemotherapy-induced neutropenia,” said Dr. Lan Huang, BeyondSpring’s CEO.
- GlobeNewswire
BeyondSpring Announces Pricing of Ordinary Shares
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,851,852 ordinary shares at a public offering price of $13.50 per share. The offering was led by Decheng Capital. The gross proceeds from the public offering are expected to be $25.0 million, before deducting underwriting discounts and commissions and other offering expenses.
- GlobeNewswire
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
BeyondSpring Inc. (the “Company” or “BeyondSpring”) (BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an underwritten public offering of its ordinary shares. The offering is being led by Decheng Capital. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares being offered.
- GlobeNewswire
BeyondSpring Enrolls First Patient in Global Phase 3 Clinical Trial with Plinabulin in combination with G-CSF to Prevent Chemotherapy-Induced Neutropenia
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN). Study 106 is enrolling patients receiving TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy plus Neulasta vs. TAC plus Plinabulin and Neulasta, to demonstrate Plinabulin’s exceptional ability to prevent CIN.
- GlobeNewswire
BeyondSpring’s Lead Asset, Plinabulin, Granted U.S. Patent Covering Methods of Treating Brain Tumors
BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,491 B2, for methods of treating a brain tumor by administering Plinabulin. The patent, which expires in 2036, covers methods for Plinabulin’s use in the treatment of brain tumors, including metastatic brain tumor, with no approved chemotherapy on the market, and glioblastoma multiforme (GBM), the most common adult brain tumor.
- GlobeNewswire
Cell Journals Publishes BeyondSpring’s New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation
NEW YORK, Oct. 08, 2019 -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today.
